Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.61 |
| ▸ | NPY2R | P49146 | 7/20 | 0.58 |
| ▸ | NPY4R | P50391 | 7/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.58 |
| ▸ | NPY1R | P25929 | 6/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 5/20 | 0.58 |
| ▸ | NTSR2 | O95665 | 3/20 | 0.58 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.58 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.58 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957024 | 1.00 | KDM1A (0.61) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL38650581 | 0.95 | KDM1A (0.62) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31302260 | 0.94 | KDM1A (0.58) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| Neurotensin SCHEMBL29851748 | 0.92 | NTSR1 (0.70) | NPY1RNTSR1NTSR2SORT1 | |
| Neurotensin SCHEMBL29357707 | 0.92 | NTSR1 (0.70) | NPY1RNTSR1NTSR2SORT1 | |
| SCHEMBL31548697 | 0.92 | NTSR1 (0.66) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31738531 | 0.92 | NTSR1 (0.66) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL29368585 | 0.90 | NTSR1 (0.63) | KDM1ANPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30102522 | 0.90 | NTSR1 (0.70) | NPY2RNPY4RNPY5RNPY1RNTSR1 | |
| SCHEMBL20808279 | 0.88 | KDM1A (0.61) | KDM1ANPY2RNPY4RNPY5RNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | NUCLIDIUM AG (CH) | 2026-01-20 | — | — | US | disclosed |
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| EP-4551251-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | Dyne Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790075-A | CNS targeting complexes and uses thereof | 达因疗法公司 | 2025-04-08 | — | — | CN | disclosed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | disclosed |
| CN-118234736-A | Method for producing peptide, method for removing protecting group, remover, and benzyl compound | 株式会社德山 | 2024-06-21 | — | — | CN | disclosed |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-06-13 | — | — | US | disclosed |
| US-20240173440-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-05-30 | — | — | US | disclosed |
| US-20240173441-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | NUCLIDIUM AG (CH) | 2024-05-30 | — | — | US | disclosed |
| WO-2024011150-A2 | CNS TARGETING COMPLEXES AND USES THEREOF | DYNE THERAPEUTICS, INC. (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2023127331-A1 | PEPTIDE PRODUCTION METHOD, PROTECTING GROUP REMOVING METHOD, REMOVING AGENT, AND BENZYL COMPOUND | 株式会社トクヤマ | 2023-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527885-B2 | High purity copper radiopharmaceutical compositions and diagnostic and therapeutic uses thereof | SSTR1, PSMA1, KLK3 | KDM1A 1551/4885NPY2R 198/4885NPY4R 744/4885 |
| US-20240173441-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | KDM1A 4286/4885NPY2R 48/4885NPY4R 77/4885 |
| US-20260137818-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | FAP, SSTR1, PSMA1 | KDM1A 2015/4885NPY2R 249/4885NPY4R 613/4885 |
| US-20240173440-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | KDM1A 4286/4885NPY2R 48/4885NPY4R 77/4885 |
| US-20240189460-A1 | HIGH PURITY COPPER RADIOPHARMACEUTICAL COMPOSITIONS AND DIAGNOSTIC AND THERAPEUTIC USES THEREOF | SSTR1, SSTR3, SSTR2 | KDM1A 4286/4885NPY2R 48/4885NPY4R 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.